Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1995 Sep;41(5):293–301. doi: 10.1007/BF01517217

Culture of tumour-infiltrating lymphocytes from melanoma and colon carcinoma: Removal of tumour cells does not affect tumour-specificity

Wilhelmina M C Mulder 1, Marij J Stukart 1, Micha Roos 1, René A W van Lier 2, John Wagstaff 3, Rik J Scheper 1, Elisabeth Bloemena 1,✉
PMCID: PMC11037598  PMID: 8536275

Abstract

The therapeutic potential of adoptive therapy using tumour-infiltrating lymphocytes (TIL) has been demonstrated in a number of clinical trials. However, freshly isolated tumour-infiltrating lymphocytes (TIL) are often impaired in their proliferative and cytotoxic responses, which limits their use in immunotherapy. Several hypotheses with regard to the poor effector function of TIL have been postulated, including the production of immunosuppressive factors by tumour cells. In a previous paper we reported the efficient expansion of immunoreactive TIL from a variety of solid tumours by stimulation with a combination of monoclonal antibodies (mAbs) against CD3 and CD28. In the present study we analysed whether this protocol would be improved by the removal of tumour cells at the start of the culture. We tested a highly immunogenic tumour, melanoma, and a poorly immunogenic tumour, colon carcinoma. Removal of tumour cells highly improved anti-CD3/CD28 stimulated expansion of TIL from colon carcinoma, resulting in a significantly higher percentage of potentially tumour-specific CD8-positive T-cells and a reduced CD4/CD8 ratio compared to expansion in the presence of tumour cells. In contrast, expansion and CD4/CD8 ratio of melanoma-derived TIL was not significantly influenced by the removal of autologous tumour cells. CD3/CD28-stimulated melanoma TIL cultured in the absence of tumour cells showed specific lysis of autologous tumour cells comparable to melanoma TIL cultured in high-dose IL2. However, no cytotoxicity could be detected in colon TIL irrespective of the culture conditions used. On the other hand, 3/8 colon carcinoma TIL cultures and 9/12 melanoma-derived TIL cultures showed IFNγ secretion upon stimulation with autologous tumour cells. We conclude that stimulation of TIL with a combination of mAbs to CD3 and CD28 in the absence of tumour cells induces efficient expansion of potentially tumour-specific cells from a highly and a poorly immunogenic tumour. Removal of tumour cells does not have a negative influence on the generation of tumour-specific T cells, while cell yield improves. Therefore, for large-scale cultures this protocol can efficiently induce the outgrowth of tumour-specific TIL, at the same time providing a useful source of autologous tumour cells that can be stored and used to direct or test antitumour specificity.

Key words: Tumour-infiltrating lymphocytes, Colon carcinoma, Melanoma, CD3 mAb, CD28 mAb, Phenotype

References

  • 1.Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA. Lysis of autologous melanoma cells by tumour-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst. 1991;83:932. doi: 10.1093/jnci/83.13.932. [DOI] [PubMed] [Google Scholar]
  • 2.Alexander JP, Kudah S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, Finke JH. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res. 1993;53:1380. [PubMed] [Google Scholar]
  • 3.Baars JW, Fonk JCM, Scheper RJ, Von Blomberg-van der Flier BME, Bril H, Van der Valk P, Pinedo HM, Wagstaff J. Treatment with tumour infiltratign lymphocytes and interleukin-2 in patients with metastatic melanoma. A pilot study. Biotherapy. 1992;4:289. doi: 10.1007/BF02172659. [DOI] [PubMed] [Google Scholar]
  • 4.Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG. Melanocyte lineagespecific antigen gp100 is recognized by melanoma-derived tumour-infiltrating lymphocytes. J Exp Med. 1994;179:1005. doi: 10.1084/jem.179.3.1005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Barnd DL, Lan MS, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumour-associated mucins by human cytotoxic T cells. Proc Natl Acad Sci USA. 1989;86:7159. doi: 10.1073/pnas.86.18.7159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Barth RJ, Jr, Mulé JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumour necrosis factor have a role in tumour regressions mediated by murine CD8+ tumour-infiltrating lymphocytes. J Exp Med. 1991;173:647. doi: 10.1084/jem.173.3.647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Chen L, Linsley PS, Hellström KE. Costimulation of T cells for tumour immunity. Immunol Today. 1993;14:483. doi: 10.1016/0167-5699(93)90262-J. [DOI] [PubMed] [Google Scholar]
  • 8.Ebert EC, Roberts AI, O'Connell SM, Robertson FM, Nagase H. Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol. 1987;138:2161. [PubMed] [Google Scholar]
  • 9.Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O'Shea JJ, Kudoh S, Klein E, Bukowski RM, Ochoa AC. Loss of T-cell receptor zeta chain and p56Ick in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993;53:5613. [PubMed] [Google Scholar]
  • 10.Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, Klein E, Tuason L, Bukowski RM. Characterization of tumour-infiltrating lymphocyte subsets fom human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferongamma secretion, and proliferation. J Immunother. 1994;15:91. doi: 10.1097/00002371-199402000-00002. [DOI] [PubMed] [Google Scholar]
  • 11.Flens MJ, Mulder WMC, Bril H, Von Blomberg van de Flier MBE, Scheper RJ, Van Lier RAW. Efficient expansion of tumour-infiltrating lymphocytes from solid tumours with combined CD3 and CD28 monoclonal antibodies. Cancer Immunol Immunother. 1993;37:323. doi: 10.1007/BF01518455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Geppert TD, Davis LS, Gur H, Wacholtz MC, Lipsky PE. Accessory cell signals involved in T-cell activation. Immunol Rev. 1990;111:5. doi: 10.1111/j.1600-065x.1990.tb00566.x. [DOI] [PubMed] [Google Scholar]
  • 13.Guillou PJ, Ramsden CW, Somers SS, Sedman PC. Suppression of the generation of lymphokine-activated killer (LAK) cells by serum-free supernatants of in vitro maintained tumour cell lines. Br J Cancer. 1989;59:515. doi: 10.1038/bjc.1989.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Hom SS, Schwartzentruber DJ, Rosenberg SA, Topalian SL. Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. J Immunother. 1993;13:18. doi: 10.1097/00002371-199301000-00003. [DOI] [PubMed] [Google Scholar]
  • 15.Hom SS, Rosenberg SA, Topalian SL. Specific immune recognition of autologous tumour by lymphocytes infiltrating colon carcinomas: analysis by cytokine secretion. Cancer Immunol Immunother. 1993;36:1. doi: 10.1007/BF01789124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hoskin CW, Reynolds T, Blay J. Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction. Cancer Immunol Immunother. 1994;38:201. doi: 10.1007/BF01525642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ioannides CG, Fisk B, Jerome KR, Irimura T, Taylor Wharton J, Finn OJ. Cytotoxic T cells from ovarian malignant tumours can recognize polymorphic epithelial mucin core peptides. J Immunol. 1993;150:3693. [PubMed] [Google Scholar]
  • 18.Jerome KR, Domenech N, Finn OJ. Tumour-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol. 1993;151:1654. [PubMed] [Google Scholar]
  • 19.Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IFC, Bast RC, Jr, Finn OJ. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 1991;51:2908. [PubMed] [Google Scholar]
  • 20.June CH, Bluesone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today. 1994;15:321. doi: 10.1016/0167-5699(94)90080-9. [DOI] [PubMed] [Google Scholar]
  • 21.Kawakami Y, Zakut R, Topalian SL, Stötter H, Rosenberg SA. Shared human melanoma antigens. Recognition by tumour-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Imm. 1992;148:638. [PubMed] [Google Scholar]
  • 22.Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumour. Proc Natl Acad Sci USA. 1994;91:3515. doi: 10.1073/pnas.91.9.3515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet. 1989;338:577. doi: 10.1016/s0140-6736(89)91609-7. [DOI] [PubMed] [Google Scholar]
  • 24.Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, De Tribolet N. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta2. J Neurosurg. 1989;71:211. doi: 10.3171/jns.1989.71.2.0211. [DOI] [PubMed] [Google Scholar]
  • 25.Liu Y, Linsley PS. Costimulation of T-cell growth. Curr Opin Immunol. 1992;4:265. doi: 10.1016/0952-7915(92)90075-p. [DOI] [PubMed] [Google Scholar]
  • 26.Miescher S, Whiteside TL, Carrel S, von Fliedner V. Functional properties of tumour-infiltrating and blood lymphocytes in patients with solid tumours: effect of tumour cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986;136:1899. [PubMed] [Google Scholar]
  • 27.Miescher S, Whiteside TL, Moretta L, von Fliedner V. Clonal and frequency analysis of tumour-infiltrating T-lymphocytes from human solid tumours. J Immunol. 1987;138:4004. [PubMed] [Google Scholar]
  • 28.Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, von Fliedner V. Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumours. Cancer Res. 1988;48:6992. [PubMed] [Google Scholar]
  • 29.Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J-L, Vivier E, Anderson P, Kiessling R. Decreased expression of the signal-transducing zeta chains in tumour-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993;53:5610. [PubMed] [Google Scholar]
  • 30.Nijhuis EWP, Van der Wiel-Van Kemenade E, Figdor CG, Van Lier RAW. Activation and expansion of tumour-infiltrating lymphocytes by anti-CD3 and anti-CD28 monoclonal antibodies. Cancer Immunol Immunother. 1990;32:245. doi: 10.1007/BF01741708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ochalek T, Von Kleist S. Study of the susceptibility of human colorectal tumour explants to LAK-cell lysis: comparison of various cytotoxicity tests. J Clin Lab Anal. 1993;7:155. doi: 10.1002/jcla.1860070305. [DOI] [PubMed] [Google Scholar]
  • 32.Okadome M, Saito T, Tsukamoto N, Sano M, Kamura T, Nakano H. Potential of human lymph node cells for antitumour activity mediated by interferon gamma. Cancer. 1991;68:2378. doi: 10.1002/1097-0142(19911201)68:11<2378::aid-cncr2820681108>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  • 33.Pandolfino M-C, Viret C, Gervois N, Guilloux Y, Davodeau F, Diez E, Jotereau F. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes. Eur J Immunol. 1992;22:1795. doi: 10.1002/eji.1830220719. [DOI] [PubMed] [Google Scholar]
  • 34.Ransom JH, Pelle BA, Hubers H, Keynton LM, Hanna MG, Jr, Pomato N. Identification of colon tumour-associated antigens by T-cell lines derived from tumour infiltrating lymphocytes and peripheral-blood lymphocytes from patients immunized with an autologous tumour cell/Bacillus Calmette-Guérin vaccine. Int J Cancer. 1993;54:734. doi: 10.1002/ijc.2910540505. [DOI] [PubMed] [Google Scholar]
  • 35.Remacle-Bonnet MM, Pommier GJ, Kaplanski S, Rance RJ, Depieds RC. Inhibition of normal allogeneic lymphocyte mitogenesis by a soluble inhibitor extracted from human colonic carcinoma. J Immunol. 1976;117:1145. [PubMed] [Google Scholar]
  • 36.Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE. Use of tumour-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med. 1988;319:1676. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  • 37.Shimizu U, Iwatsuki S, Herberman RB, Whiteside TL. Effects of cytokines on in vitro growth of tumour-infiltrating lymphocytes obtained from human primary and metastatic liver tumours. Cancer Immunol Immunother. 1993;32:280. doi: 10.1007/BF01789045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Stoeck M, Miescher S, Qiao L, Capasso P, Barras C, von Fliedner V. Stimulation of FACS-analysed CD4+ and CD8+ human tumour-infiltrating lymphocytes with ionomycin+phorbol-12,13-dibutyrate does not overcome their proliferative deficit. Clin Exp Immunol. 1990;79:105. doi: 10.1111/j.1365-2249.1990.tb05135.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Svennevig JL, Lunde OC, Holter J, Björgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer. 1984;49:375. doi: 10.1038/bjc.1984.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Tefany FJ, Barnetson R StC, Halliday GM, McCarthy SW, McCarthy WH. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melenoma. J Invest Dermatol. 1991;97:197. doi: 10.1111/1523-1747.ep12479662. [DOI] [PubMed] [Google Scholar]
  • 41.Thompson CB, Linsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc natl Acad Sci USA. 1989;86:1333. doi: 10.1073/pnas.86.4.1333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA. Immunotherapy with patients with advanced cancer using tumour infiltrating lymphocytes and recombinant IL-2: A pilot study. J Clin Oncol. 1988;6:839. doi: 10.1200/JCO.1988.6.5.839. [DOI] [PubMed] [Google Scholar]
  • 43.Traversari C, Van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumour antigen MZ2-E. J Exp Med. 1992;176:1453. doi: 10.1084/jem.176.5.1453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Viret C, Davodeau F, Guilloux Y, Bignon J-D, Semana G, Breathnach R, Jotereau F. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumour-infiltrating lymphocytes. Eur J Immunol. 1993;23:141. doi: 10.1002/eji.1830230123. [DOI] [PubMed] [Google Scholar]
  • 45.Vose BM, Vánky F, Klein E. Human tumour-lymphocyte interaction in vitro. V. Comparison of the reactivity of tumour-infiltrating, blood and lymph-node lymphocytes with autologous tumour cells. Int J Cancer. 1977;20:895. doi: 10.1002/ijc.2910200612. [DOI] [PubMed] [Google Scholar]
  • 46.Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V. Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumours. Int J Cancer. 1986;37:803. doi: 10.1002/ijc.2910370602. [DOI] [PubMed] [Google Scholar]
  • 47.Whiteside TL, Parmiani G. Tumour-infiltrating lymphocytes: their phenotype, functions and clinical use. Cancer Immunol Immunother. 1994;39:15. doi: 10.1007/BF01517175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wiebke EA, Lotze MT, Rosenberg SA. Tumour cell susceptability to lysis: marked increase in lysis by tumour-infiltrating lymphocytes following target stimulation with interferon gamma and tumour necrosis factor alpha — implications for immunotherapy. Surg Forum. 1987;38:436. [Google Scholar]
  • 49.Wysocki LJ, Sato VL. “Panning” for lymphocytes: a method for cell selection. Proc Natl Acad Sci USA. 1978;75:2844. doi: 10.1073/pnas.75.6.2844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Zocchi MR, Poggi A, Crosti F, Tongiani S, Rugarli C. Signalling in human tumour infiltrating lymphocytes: the CD28 molecule is functional and is physically associated with CD45RO molecule. Eur J Cancer. 1992;28A:749. doi: 10.1016/0959-8049(92)90108-e. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES